Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

詳細記述

書誌詳細

主要な著者:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2020-07-01
シリーズ:	Endocrinology, Diabetes & Metabolism
主題:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
オンライン･アクセス:	https://doi.org/10.1002/edm2.159
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!